ImmunoForge’s proprietary technology platform for modulating pharmacokinetics has extensive clinical and pre-clinical experience. ELP is based on a naturally-occurring amino acid sequence, can be optimized for desired drug exposure and has broad utility across a wide-range of drug classes and therapeutic areas. ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection. Favorable safety-and-tolerability profile has been well-characterized in multiple clinical trials.
Our proprietary technology platform is based on recombinant biopolymers called elastin-like polypeptides (ELPs), which comprise individual building blocks derived from a five-amino acid repeat motif found in the human protein elastin. This five-amino acid motif is repeated multiple times to form the ELP biopolymer.
Our ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection.
Our strategy is to apply our ELP technology to proteins and peptides with well-characterized therapeutic activities but suboptimal half-lives to improve their pharmacokinetics, enable their use as pharmaceutical products and allow for more convenient dosing regimens.